Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01373931 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2216684 in Healthy Females
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01373931 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 20 participants.
The verdict
NCT01373931, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study involves a single dose of 18 milligrams (mg) LY2216684 taken as 1 or 2 tablets by mouth. The study will evaluate effect of LY2216684 on the pharmacokinetics of an oral contraceptive Ortho Cyclen®. This study will run approximately 93 days.
Interventions
- DRUG Placebo
- DRUG LY2216684
- DRUG Ortho Cyclen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01373931
The ClinicalTrials.gov registry entry for NCT01373931 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01373931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01373931 about?
NCT01373931 is a clinical study titled "A Study of LY2216684 in Healthy Females". This study involves a single dose of 18 milligrams (mg) LY2216684 taken as 1 or 2 tablets by mouth. The study will evaluate effect of LY2216684 on the pharmacokinetics of an oral contraceptive Ortho Cyclen®. This study will run approximately 93 days.
What is the current status of trial NCT01373931?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-06. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01373931?
The interventions under investigation include: Placebo (DRUG), LY2216684 (DRUG), Ortho Cyclen (DRUG).
Who is sponsoring clinical trial NCT01373931?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.